Preferred Label : Heterocyclic Compounds, 4 or More Rings;
MeSH definition : A class of organic compounds containing four or more ring structures, one of which
is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle
may be either aromatic or nonaromatic.; A class of heterocyclic compounds that include four or more fused rings. Both aromatic
or non-aromatic ring structures are included in this category.;
MeSH synonym : heterocyclic cpds, 4 or more rings; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds with Four or More Rings;
MeSH hyponym : 5-Ring Heterocyclic Compounds; Heterocyclic Compounds, 5 Ring; Heterocyclic Cpds, 5 Ring; Five Ring Heterocyclic Compounds; Fused Heterocyclic Compounds, Five-Ring; Fused Heterocyclic Compounds, Five Ring; 4-Ring Heterocyclic Compounds; Heterocyclic Compounds, 4 Ring; Heterocyclic Cpds, 4 Ring; Four Ring Heterocyclic Compounds; Fused Heterocyclic Compounds, Four-Ring; Fused Heterocyclic Compounds, Four Ring;
MeSH annotation : GEN; prefer specifics; used for mapping supplementary chemicals; general or unspecified; prefer specifics;
Is substance : O;
Origin ID : D006576;
UMLS CUI : C0019402;
- Allowable qualifiers
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- 0433YC1 [MeSH Supplementary Concept]
- 0433YC2 [MeSH Supplementary Concept]
- 1,10,10-trimethyl-2-(3,4,5-trimethoxyphenyl)-1,2,2a,4,10,10a-hexahydro-3H-cyclobuta(4,5)pyrano(3,2-c)quinolin-3-one [MeSH Supplementary Concept]
- 11,12,24,25-tetrahydro-28,34-dimethoxy-3,6,16,19,31,37-hexamethyl-1,21(1',3')-8,14(1'',3'')-dibenzeno-10H,23H-tetrabenzo(f,h,o,z)(1,5,10,14)tetraoxacyclooctadecane [MeSH Supplementary Concept]
- 11-fluoro-2,4,8-trimethyl-2,4,4a,6-tetrahydro-1H,1'H-spiro(isoxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(3'H)-trione [MeSH Supplementary Concept]
- 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene [MeSH Supplementary Concept]
- 15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triazatetracyclo(18.3.1.1(2,5).1(14,18))hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene [MeSH Supplementary Concept]
- 18-thia-6,14,16,19,20-pentaazapentacyclo(12.6.0.0(2,6).0(8,13).0(15,19))icosa-1(20),8,10,12,15-pentaene-7,17-dione [MeSH Supplementary Concept]
- 19(5),24(5)-dibromo-4,7,13,16,20,23-hexaoxa-1,10-diaza-19(1,2),24(1,2)-dibenzabicyclo(8.8.6)tetracosaphane [MeSH Supplementary Concept]
- 2,3,10,11-tetramethoxy-8a,16a-diphenyl-8,8a,13,14,16,16a-hexahydropyrazino(2,1-a-5,4-a')diisoquinoline-5(6H)-one [MeSH Supplementary Concept]
- 27-cyclohexyl-12,13,16,17-tetrahydro-22-methoxy-11,17-dimethyl-10,10-dioxide-2,19-methano-3,7:4,1-dimetheno-1H,11H-14,10,2,9,11,17-benzoxathiatetraazacyclo
docosine-8,18(9H,15H)-dione [MeSH Supplementary Concept]
- 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic
acid tert-butyl ester [MeSH Supplementary Concept]
- 5,14-dioxo-12-(2-phenylalanine-N-ylethyl-1-yl)-1,2,3,5,5a,6,11,12,14,14a-decahydro-5H,14H-pyrolo(1,2-4,5)pyrazino(1,2-1,6)pyrido(3,4-b)indole [MeSH Supplementary Concept]
- 5,5-difluoro-2,8-diphenyl-11-(trifluoromethyl)-5H-thieno(2',3'-4,5)pyrrolo(1,2-c)thieno(2',3'-4,5)pyrrolo(2,1-f)(1,3,2)diazaborinin-4-ium-5-uide [MeSH Supplementary Concept]
- 6,14-dichloro-3,11-dimethyl-1,3,9,11-tetrahydro-5,13-dioxa-7,15-diazadiimidazo-(4,5-b:4',5'-m)pentacene-2,10-dione [MeSH Supplementary Concept]
- 6-chloro-10-(2-methanesulfonylmethylamino)-17-(4-methylpiperazin-1-yl)-19-methoxy-2,4,8,22-tetraazatetracyclo(14.3.1.13,7.19,13)docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene [MeSH Supplementary Concept]
- 8a,16a-diphenyl-5,6,8,8a,13,14,16,16a-octahydropyrazino(2,1-a-5,4-a')diisoquinoline-2,3,10,11-tetraol [MeSH Supplementary Concept]
- AX 7503 [MeSH Supplementary Concept]
- Atto590 [MeSH Supplementary Concept]
- Atto655 [MeSH Supplementary Concept]
- BMH-21 [MeSH Supplementary Concept]
- BQ-869 [MeSH Supplementary Concept]
- CCF4-AM [MeSH Supplementary Concept]
- CIM0216 [MeSH Supplementary Concept]
- CW209E [MeSH Supplementary Concept]
- Cl958 [MeSH Supplementary Concept]
- ETC-159 [MeSH Supplementary Concept]
- HC-070 [MeSH Supplementary Concept]
- ITI-214 [MeSH Supplementary Concept]
- KD025 [MeSH Supplementary Concept]
- KNT 63 [MeSH Supplementary Concept]
- KP372-1 [MeSH Supplementary Concept]
- LC-0296 [MeSH Supplementary Concept]
- MK-4882 [MeSH Supplementary Concept]
- MK-7285 [MeSH Supplementary Concept]
- MK-8325 [MeSH Supplementary Concept]
- MK-8831 [MeSH Supplementary Concept]
- MPC1001 [MeSH Supplementary Concept]
- MRK-409 [MeSH Supplementary Concept]
- QC6352 [MeSH Supplementary Concept]
- SA22465 [MeSH Supplementary Concept]
- SAN4825 [MeSH Supplementary Concept]
- SJ733 [MeSH Supplementary Concept]
- SR9238 [MeSH Supplementary Concept]
- SRA737 [MeSH Supplementary Concept]
- SRT1460 [MeSH Supplementary Concept]
- SRT1720 [MeSH Supplementary Concept]
- SRT2183 [MeSH Supplementary Concept]
- TA I-95 [MeSH Supplementary Concept]
- TMP778 [MeSH Supplementary Concept]
- TP 300 [MeSH Supplementary Concept]
- WMC-79 [MeSH Supplementary Concept]
- evodine [MeSH Supplementary Concept]
- methyl 8-(3-furyl)-2a,4,5,5a,6,6a,8,9,9a,10a,10b,10c-dodecahydro-3-hydroxy-2a,5a,6a,7-tetramethyl-5-(3-methylbut-2-enoyloxy)-2H,3H-cyclopenta(4',5')furo(2',3'-6,5)benzo(cd)isobenzofuran-6-acetate [MeSH Supplementary Concept]
- mopanol [MeSH Supplementary Concept]
- Semantic type(s)
A class of organic compounds containing four or more ring structures, one of which
is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle
may be either aromatic or nonaromatic.
A class of heterocyclic compounds that include four or more fused rings. Both aromatic
or non-aromatic ring structures are included in this category.
https://www.has-sante.fr/jcms/p_3280914/fr/biktarvy-emtricitabine/-bictegravir-sodique/-tenofovir-alafenamide
2021
false
false
false
France
Emtricitabine
evaluation of the transparency committee
fumarates
Tenofovir
bictegravir
bictegravir
tenofovir alafenamide
tenofovir alafenamide
adenine
Heterocyclic Compounds, 4 or More Rings
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
drug combinations
---
https://www.has-sante.fr/jcms/p_3224423/fr/epclusa
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
sofosbuvir-velpatasvir drug combination
antiviral agents
Product containing only sofosbuvir and velpatasvir in oral dose form (medicinal product
form)
sofosbuvir and velpatasvir
hepatitis C, chronic
adult
adolescent
child
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.has-sante.fr/jcms/p_3152658/fr/vosevi
2020
false
false
false
France
sofosbuvir, velpatasvir and voxilaprevir
drug combinations
Sofosbuvir
velpatasvir
voxilaprevir
adult
administration, oral
treatment outcome
insurance, health, reimbursement
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
carbamates
Heterocyclic Compounds, 4 or More Rings
sulfonamides
macrocyclic compounds
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.has-sante.fr/jcms/p_3152667/fr/epclusa
2020
false
false
false
France
Sofosbuvir
velpatasvir
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
Epclusa
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
---
https://www.has-sante.fr/jcms/p_3115175/fr/epclusa
2019
false
false
false
France
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
sofosbuvir-velpatasvir drug combination
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.ema.europa.eu/medicines/human/EPAR/Biktarvy
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Heterocyclic Compounds, 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Emtricitabine
drug combinations
tenofovir alafenamide
tenofovir alafenamide
drug approval
europe
emtricitabine, tenofovir alafenamide and bictegravir
hiv infections
adult
drug interactions
pregnancy
breast feeding
administration, oral
HIV integrase inhibitors
HIV integrase inhibitors
anti-hiv agents
anti-hiv agents
reverse transcriptase inhibitors
reverse transcriptase inhibitors
product surveillance, postmarketing
aged
drug evaluation, preclinical
treatment outcome
bictegravir
bictegravir
Tenofovir
Emtricitabine
adenine
tenofovir alafenamide
tenofovir alafenamide
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00405
2018
false
false
false
Canada
French
drug information
drug combinations
drug approval
canada
bictegravir
bictegravir
emtricitabine, tenofovir alafenamide and bictegravir
Emtricitabine
Emtricitabine
tenofovir alafenamide
tenofovir alafenamide
treatment outcome
hiv infections
anti-hiv agents
anti-hiv agents
reverse transcriptase inhibitors
reverse transcriptase inhibitors
HIV integrase inhibitors
HIV integrase inhibitors
adult
administration, oral
tenofovir alafenamide
tenofovir alafenamide
adenine
adenine
adenine
Heterocyclic Compounds, 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
Tenofovir
---
https://www.has-sante.fr/portail/jcms/c_2873692/fr/biktarvy
2018
false
false
false
France
French
Heterocyclic Compounds, 4 or More Rings
drug combinations
tenofovir alafenamide
emtricitabine, tenofovir alafenamide and bictegravir
hiv infections
adult
administration, oral
HIV integrase inhibitors
anti-hiv agents
reverse transcriptase inhibitors
aged
treatment outcome
bictegravir
evaluation of the transparency committee
Tenofovir
Emtricitabine
adenine
tenofovir alafenamide
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Onzeald
2018
false
false
false
United Kingdom
French
English
etirinotecan pegol
etirinotecan pegol
syndication feed
summary of product characteristics
package leaflet
drug evaluation
gait, nos
denied
Heterocyclic Compounds, 4 or More Rings
polyethylene glycols
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds
---
https://www.ema.europa.eu/medicines/human/EPAR/Vosevi
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug approval
europe
treatment outcome
product surveillance, postmarketing
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
drug interactions
pregnancy
breast feeding
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
drug evaluation, preclinical
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
NS3-4A serine protease, Hepatitis C virus
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.has-sante.fr/portail/jcms/c_2817995/fr/vosevi
2017
false
false
false
France
French
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
treatment outcome
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
insurance, health, reimbursement
evaluation of the transparency committee
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Epclusa
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
velpatasvir
velpatasvir
drug combinations
Sofosbuvir
Sofosbuvir
antiviral agents
antiviral agents
pregnancy
breast feeding
drug interactions
hepatitis C, chronic
adult
administration, oral
drug therapy, combination
NS-5a protein, hepatitis C virus
enzyme inhibitors
enzyme inhibitors
RNA-Dependent RNA Polymerase
product surveillance, postmarketing
aged
drug evaluation, preclinical
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
NS-5 protein, hepatitis C virus
viral nonstructural proteins
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00329
2016
false
false
false
Canada
French
drug information
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa-sofosbuvir/velpatasvir-association-fixe-d-antiviraux-a-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
drug combinations
Sofosbuvir
Sofosbuvir
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
velpatasvir
velpatasvir
hepatitis C, chronic
adult
guidelines for drug use
sofosbuvir-velpatasvir drug combination
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
drug combinations
---